Streetbeat News

Revenues

FOLD

Amicus Therapeutics forecasts a total revenue growth of 25%-30% for 2024, with its key product Galafold expected to see revenue growth of 13%-17%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:09 am

ADV

Advantage Solutions (NASDAQ:ADV) reported Q1 sales of $906M, surpassing the analyst consensus estimate of $867.515M by 4.44%, but marking a 10.47% decrease from the previous year's $1.012B.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:09 am

PZZA

Papa John's International reported a decline in Q1 total comparable store sales by 2%, with international sales down by 2.6% and North America sales down by 1.8%. The report details a decrease across various segments, including domestic company-owned restaurants, North America franchised restaurants, and system-wide sales, contrasting with the previous year's growth in several areas.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:05 am

RPRX

Royalty Pharma projects its FY24 portfolio receipts to be between $2.6 billion and $2.7 billion.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:05 am

VTRS

Viatris has updated its revenue expectations for 2024, projecting revenues to be between $14.98B and $15.48B. This is a downward revision from its prior guidance of $15.25B-$15.75B and is slightly below the consensus estimate of $15.19B.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:05 am

LCUT

Lifetime Brands projects its FY24 adjusted EPS to be between $0.69 and $0.78, surpassing the estimated $0.67. The company also forecasts net sales to range from $690M to $730M, closely aligning with the estimated $691.09M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:04 am

RPRX

Royalty Pharma (NASDAQ:RPRX) reported Q1 sales of $568.00M, missing the consensus estimate of $663.22M by 14.36%, marking a 16.96% decrease from the previous year's $684.00M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:02 am

BLUE

bluebird bio (NASDAQ:BLUE) reported Q1 sales of $18.600 million, missing the consensus estimate of $19.551 million by 4.86%, but marking a 681.18% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:01 am

HAE

Haemonetics projects its 2024 revenue to grow by 5%-8% on a reported basis and 0%-3% on an organic basis, indicating a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:59 am

VYX

NCR Voyix has reiterated its fiscal year 2024 guidance, projecting total revenue to be between $3.60 billion and $3.70 billion, aligning closely with the estimated $3.633 billion.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:54 am